Lazolvan rino nasal spray 10 ml

Release form, composition
Spray Lasolvan Reno nasal pale yellow color, transparent, with the smell of eucalyptus.
1 ml:
Tramazolin hydrochloride monohydrate 1.265 mg, which corresponds. the content of tramazolin hydrochloride 1.18 mg
Excipients: citric acid monohydrate - 3.906 mg, sodium hydroxide - 2.23 mg, benzalkonium chloride - 202 μg, hypromellose (hydroxypropylmethylcellulose) - 506 μg, povidone - 30.36 mg, glycerol 85% - 10.12 mg, Magnesium sulfate, heptahydrate magnesium - 714 mg, Hexahydrate chloride - 510 mcg, Calcium chloride dihydrate - 164 mcg, sodium bicarbonate - 20 mcg, sodium chloride - 2.651 mg, cineol (eucalyptol) - 101 mcg, levomenthol (L-menthol) - 202 mcg, camphor racemic - 202 mcg, water purified - up to 1 ml.

Farmgroup:anti-congestive agent - a vasoconstrictor (alpha adrenomimetic).
Pharmaceutical action:The active ingredient of the drug Lasolvan® Rino - tramazolin hydrochloride, alpha2-adrenomimetik, causes vasoconstriction. When applied to the mucous membranes of the nose due to vasoconstrictive action of the drug reduces puffiness. As a result, the patency of the nasal passages is quickly restored, nasal breathing is facilitated for a long time.
The action of the drug begins during the first 5 minutes and lasts 8-10 hours.
Pharmacokinetics:Pharmacokinetic studies in humans have not been conducted. The pharmacokinetics of tramazolin has been studied in rats, rabbits and monkeys. It has been shown that after the use of the drug, 50-80% of the administered dose is absorbed orally or intranasally. Tramazolin and its metabolites are distributed in all internal organs, Cmax is noted in the liver.
After oral or topical administration, the major metabolites are determined in the urine. Terminal T1 / 2 ranges from 5 to 7 h.
Indications:- swelling of the nasal mucosa, nasal congestion caused by acute respiratory infections and / or pollinosis (rhinitis, hay fever);
- with sinusitis and otitis media (eustachitis) to facilitate the outflow of the contents of the paranasal sinuses (as recommended by the doctor).
Category of action on the fetus:Long experience of use shows that Lasolvan® Rino does not have a negative effect on pregnancy. The safety of the drug during lactation is not confirmed.
Lasolvan® Rino should not be used in the first trimester of pregnancy. In the later stages of pregnancy and during breastfeeding, the use of the drug is allowed only after consulting a doctor.

Contraindications:- angle-closure glaucoma;
- atrophic rhinitis;
- surgery on the skull, carried out through the nasal cavity (in history);
- children's age up to 6 years;
- hypersensitivity to tramazolin hydrochloride or benzalkonium hydrochloride, as well as to other components of the drug Lasolvan Reno.

Carefully

Patients with arterial hypertension, heart disease, hyperthyroidism, prostatic hyperplasia, pheochromocytoma, porphyria, the drug should be used only on the recommendation of a doctor due to the potential risk of systemic absorption of the drug.

Care should be taken when taking MAO inhibitors, tricyclic antidepressants, vasopressor drugs and antihypertensive drugs.
Dosing:Adults and children over 6 years old Lasolvan Reno is prescribed one injection in each nasal passage (up to 4 injections in each nasal passage per day).
Do not use the drug for more than 5-7 days without a doctor's prescription.

Instructions for using the bottle with a metering device:
Clean the nasal passages before the injection.
1. Remove the protective cap.
2. Before first use, it is necessary to make several injections into the air before the appearance of a stable aerosol cloud. After that, the dosing device is ready for use.
3. Insert the tip into the nasal passage and make one injection.
Repeat the procedure for the other nasal passage. After extracting the tip, make a normal inhale through the nose.
4. Put on the protective cap.
It is recommended to clean the tip after each use.

Side effect: On the part of the nervous system: rarely (≥0.01% and <0.1%) - dizziness, impaired taste sensations; infrequently (≥0.1% and <1%) - headache, anxiety; frequency is not installed * - drowsiness, sedation, hallucinations, insomnia.
Since the cardiovascular system: infrequently (≥0.1% and <1%) - heartbeat; frequency is not installed * - arrhythmia, tachycardia, an increase in blood pressure.
On the part of the respiratory system: often (≥1% and <10%) - nasal discomfort; infrequently (≥0.1% and <1%) - swelling of the nose, dry nose, rhinorrhea, sneezing; rarely (≥0.01% and <0.1%) - epistaxis.
On the part of the digestive system: infrequently (≥0.1% and <1%) - nausea.
On the part of the immune system: the frequency has not been established * - hypersensitivity.
On the part of the skin and subcutaneous tissues **: frequency not established * - rash, itching, swelling of the skin.
Other: frequency not set * - swelling of the mucous membrane **, fatigue.
* Undesirable effects, whose connection with the drug was regarded as possible, registered with the widespread use of the drug Lasolvan Reno. The frequency of these rare events is difficult to estimate.
** Like hypersensitivity symptoms.

Overdose:Symptoms: following an increase in blood pressure and tachycardia, it is possible (especially in children) a fall in blood pressure, the development of shock, reflex bradycardia, a decrease in body temperature.
By analogy with other alpha sympathomimetics, the clinical picture of intoxication can be indistinct, since the phases of stimulation and depression of the central nervous system and the cardiovascular system can replace each other.
Especially in children, intoxication leads to effects on the central nervous system with the development of seizures and coma, bradycardia, respiratory depression. Symptoms of CNS stimulation are anxiety, agitation, hallucinations and convulsions.Symptoms of depression of the central nervous system include a decrease in body temperature, lethargy, drowsiness, and coma.

In addition, the following symptoms may develop: mydriasis, miosis, increased sweating, fever, pallor, cyanosis of the lips, impaired function of the cardiovascular system (including cardiac arrest); respiratory failure (including respiratory failure, respiratory arrest); psychological disorders.

Treatment: in case of a nasal overdose, immediately flush or clear the nose. Symptomatic treatment may be required.
Interaction:Some antidepressants (MAO inhibitors and tricyclic antidepressants) and vasoconstrictor drugs with simultaneous administration can cause an increase in blood pressure.

Combined use with tricyclic antidepressants can lead to the development of arrhythmias.
Simultaneous use with antihypertensive drugs (especially those that affect the sympathetic nervous system) can lead to different cardiovascular effects.
Special instructions:If after 7 days of taking Lasolvan Reno there are no positive changes in symptoms, you should decide whether to stop taking the drug or continue the treatment. Prolonged use of nasal vasoconstrictor drugs can lead to the development of chronic inflammation and nasal congestion, as well as atrophy of the nasal mucosa.
Avoid contact with eyes.

Influence on ability to drive motor transport and control mechanisms
Studies on the effect of the drug Lasolvan Reno on the ability to drive a car and machinery have not been conducted. However, when taking the drug, such undesirable effects as hallucination, drowsiness, sedation, dizziness and fatigue are possible. Therefore, care must be taken when driving and operating machinery.
If the above side effects appear, you must avoid performing potentially dangerous tasks such as driving a car or machinery.